Health technology assessment in middle-income countries: recommendations for a balanced assessment system

References

• Swiss Network for Health Technology Assessment. Available from: http://www.snhta.ch/ [cited 4 January 2014].
   Google Scholar
• International Network of Agencies for Health Technology Assessment. Available from: http://www.inahta.net [cited 4 January 2014].
   Google Scholar
• Garrido MV , Kristensen FB , Nielsen CP , Busse R . Health technology assessment and health policy-making in Europe. 2008; Copenhagen: WHO.
   Google Scholar
• EUnetHTA. EUnetHTA handbook on HTA capacity building. Work package 8. 2008; Barcelona: Catalan Agency for Health Technology Assessment and Research.
   Google Scholar
• Dankó D How can value be measured and valued? ISPOR 5th Asia-Pacific Conference, Taipei, 2 September 2012.
   Google Scholar
• Oortwijn W , Mathijssen J , Banta D . The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries. Health Policy. 2010; 95: 174–84.
   Web of Science ®Google Scholar
• Callahan KP , Bridges JF . Using comparative effectiveness research to inform decision-making: Is there a role of economic evaluation?. J Comp Eff Res. 2012; 1(4): 299–301.
   Web of Science ®Google Scholar
• Drummond MF , Sculpher MJ , Torrance GW , O'Brien BJ , Stoddart GL . Methods for the economic evaluation of health care programmes. 2005; Oxford, UK: Oxford University Press.
   Google Scholar
• Cleemput I , Neyt M , Thiry N , De Laet C , Leys M . Threshold values for effectiveness in health care. 2008; Brussels: KCE.
   Google Scholar
• Donaldson C , Currie G , Mitton C . Cost-effectiveness analysis in health care – contraindications. BMJ. 2002; 325: 891–4.
   PubMed Web of Science ®Google Scholar
• Landa K. The latest developments in P and R policy in Poland – focus on systemic efficiency. (no date). Available from: http://www.lse.ac.uk/businessAndConsultancy/LSEConsulting/conferences/landa.pdf [cited 4 January 2014].
   Google Scholar
• Kanavos P, Angelis A. Multiple criteria decision analysis for value based assessment of new medical technologies: A conceptual framework. Working paper No. 33. London School of Economics and Political Science; 2013. Available from: http://www.lse.ac.uk/LSEHealthAndSocialCare/pdf/LSEHealthworkingpaperseries/LSEH-WP33_final.pdf [cited 4 January 2014].
   Google Scholar
• O'Donnell JC , Pham SV , Pashos CL , Miller DW , Smith MD . Health technology assessment in evidence-based health care reimbursement decisions around the world: An overview. Value Health. 2009; 12(2): 1–5.
   PubMed Web of Science ®Google Scholar
• Mills A , Glied S , Smith PC . Health systems in low- and middle-income countries. The Oxford handbook of health economics. 2011; Oxford, UK: Oxford University Press. 30–57.
   Google Scholar
• ISPOR. ISPOR global health care system roadmaps. Available from: http://www.ispor.org/HTARoadMaps/Default.asp [cited 4 January 2014].
   Google Scholar
• Marusakova E , Bielik J . Application of health technology assessment and pharmacoeconomics in the decision-making process in selected EU member states. 12–14 September 2013; ISPOR 4th Latin America Conference, Buenos Aires.
   Google Scholar
• Towse A , Buxton M . Three challenges to achieving better analysis for better decisions: Generalisability, complexity and thresholds. 2006; London: Office of Health Economics. 1–13. OHE briefing No 42.
   Google Scholar
• Gulácsi L , Orlewska E , Péntek M . Health economics and health technology assessment in Central and Eastern Europe: A dose of reality. Eur J Health Econ. 2012; 13: 525–31.
   PubMed Web of Science ®Google Scholar
• Dankó D . Assessing innovative medicines in middle-income countries. Third Pharmacoeconomics Conference of the Serbian Pharmaceutical Association. Belgrade, 24 May 2013.
   Google Scholar
• Mathauer I , Wittenbecher F . Hospital payment systems based on diagnosis-related groups: Experiences in low- and middle-income countries. Bull World Health Organ. 2013; 91(10): 746–56A.
   Web of Science ®Google Scholar
• Kaló Z , Bodrogi J , Boncz I , Dózsa CS , Jóna G , Kövi R et al. . Capacity building for HTA implementation in middle-income countries: The case of Hungary. Value Health Reg Issues. 2013; 2: 264–6.
   PubMedGoogle Scholar
• Birch S , Gafni A . The biggest bang for the buck or bigger bucks for the bang: The fallacy of the cost-effectiveness threshold. J Health Serv Res Policy. 2006; 11(1): 46–51.
   PubMedGoogle Scholar
• Le Pen C . The drug budget silo mentality: The French case. Value Health. 2003; 6(1): 10–19.
   Web of Science ®Google Scholar
• Drummond M , Barbieri M , Cook J , Glick HA , Lis J , Malik F et al. . Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009; 12(4): 409–18.
   PubMed Web of Science ®Google Scholar
• Goeree R , He J , O'Reilly D , Tarride JE , Xie F , Lim M et al. . Transferability of health technology assessments and economic evaluations: A systematic review of approaches for assessment and application. Clinicoecon Outcomes Res. 2011; 3: 89–104.
   PubMedGoogle Scholar
• Kaló Z , Landa K , Dolezal T , Vokó Z . Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. Eur J Cancer Care. 2012; 21(4): 442–9.
   PubMed Web of Science ®Google Scholar